HOME >> MEDICINE >> NEWS
Data showed improved quality of life and patient satisfaction with SYMBICORT

Wilmington, DE May 22, 2007 New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo. The results from these two 12-week randomized, double-blind trials were presented at the American Thoracic Society (ATS) 2007 International Conference held in San Francisco, May 18-23.

"Asthma is a chronic disease that can have a significant effect on patients' day-to-day routine, including participating in activities, such as walking to the store or even playing with their children," said Dr. Kevin R. Murphy, Clinical Professor, University of Nebraska Medical Center. "For the millions of asthma sufferers in the U.S., and especially for those whose condition is not adequately controlled with their current medication, SYMBICORT will provide a new option for patients to help manage and control their asthma, allowing them to get back to their daily activities."

SYMBICORT is a recently approved, combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma. Studies of patients treated with SYMBICORT demonstrated clinically significant improvement in lung function occurring within 15 minutes of beginning treatment. SYMBICORT has safety data in long-term studies of up to one year, and has a robust cardiac safety profile.

"The studies presented at this year's ATS conference provided valuable data on asthma control and asthma-related quality of life with SYMBICORT," said Chris O'Brien, Senior Director, Medical Science, AstraZeneca. "Asthma sufferers will have a new, rapid-acting combination treatment to help them achieve asthma control."

Administere
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
22-May-2007


Page: 1 2 3

Related medicine news :

1. New analysis showed UC patients in clinical remission had higher rates of employment
2. ROZEREM (ramelteon) showed significant reduction in time to fall asleep
3. New study showed ramelteon helped adults with chronic insomnia fall asleep, sleep longer
4. LSUHSC awarded designation resulting in improved patient safety and outcomes
5. ACP supports improved access to information on relative strengths and weaknesses
6. Performance-related financial incentives for hospitals not linked with improved quality of care
7. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
8. Alzheimers weight gain initiative also improved patients intellectual abilities
9. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Lymph node evaluation linked to improved survival for colon cancer patients

Post Your Comments:
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair ... following statement following the deadly earthquake in Nepal: , ... in the deaths of more than 1,000 people. ... Nepal, Bangladesh, India and other parts of South Asia. ... the people of Nepal and the families of the ...
(Date:4/25/2015)... April 25, 2015 By definition, a CIO’s ... for the enterprise relying on their judgement and expertise to ... But according to an article published in National Mortgage ... actually be doing a disservice to their responsibilities by focusing ... and t’s are crossed when it comes to company policy ...
(Date:4/25/2015)... April 25, 2015 Parker and Sons projects ... cooling, has spiked in Arizona alongside the growing economy. As ... forty employees for April to help account for the rising ... employees in April is something we are enthusiastic about. It ... Paul Kelly, president at Parker and Sons. , Indeed, Parker ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day ... in the nation! This year, on May 5th, 2015, Secura ... take DI Day on the road by supporting the first ... RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants and ... change by stating, "The first Twin Cities DI Day was ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
(Date:4/24/2015)... DUBLIN , Apr. 24, 2015 /PRNewswire/ ... ) has announced the addition of the ... Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & ... Institute) - Global Forecast to 2020" ... global laboratory accessories market is expected to ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. (NYSE: ... and increased its five-year revolving credit facility to $120 ... accordion feature that will allow the company to increase ... $30.0 million, subject to securing additional commitments from existing ... the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
Cached News: